Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of OVX836 Co-administered with Quadrivalent Inactivated Influenza Vaccine
NCT05284799Phase 2Completed
- Sponsor
- Osivax
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza comparing OVX836 + QIV, QIV + Placebo and OVX836 + Placebo (3 arms). Primary endpoints: Number of seroconversion determined using Hemagglutination-Inhibition assay at Day 29, Proportion of subjects achieving a titer ≥1:40 determined using Hemagglutination-Inhibition assay at Day 29 and 6 more. Started May 2022; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05284799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284799.